Sermorelin
Also known as: GHRH 1-29 · Sermorelin Acetate
Sermorelin is the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). FDA-approved for pediatric GHD until 2008; since then sold compounded for off-label adult anti-aging and recovery use. Less popular than ipamorelin in the modern stack, but still common in US compounding pharmacies.
Last reviewed · Panya.health editorial
Panya scores vendors against an 11-signal rubric. Vendors at or above 70 out of 100 are routable; below 70 are documented but get no Panya affiliate link. For prescription peptides like Mounjaro and Wegovy, Panya routes today through licensed clinicians. For research peptides like Sermorelin, vendor scorecards land in a follow-up sprint after legal review and payment processor selection. Until then, the page surfaces commonly-mentioned vendor names so adults can do their own diligence. We do not yet earn commission on any Sermorelin vendor.
Not medical advice. Sermorelin is not approved for human medical use in most jurisdictions. The data below is what users do; it is not what regulators have validated. You decide your risk profile.
What it does, and how
Sermorelin binds the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs, triggering pulsatile endogenous growth hormone release. Unlike exogenous HGH injection, sermorelin preserves the natural pulsatile pattern and is regulated by negative feedback (somatostatin shuts the pulse down at the right moment), which is the basis of the 'safer than HGH' positioning. Effective half-life is short (10 to 20 minutes plasma), but the GH pulse it triggers lasts longer. Pediatric efficacy was demonstrated in 1990s trials before sermorelin's FDA approval was withdrawn for commercial reasons (not safety). Adult use is off-label and rests on small-trial extrapolation.
Typical practice
Community practice runs 100 to 500 mcg per day, subcutaneous, taken at night before sleep so the pulse aligns with natural deep-sleep GH peak. Cycles typically 3 to 6 months continuous, sometimes 5 days on / 2 days off to preserve receptor sensitivity. Reconstitution typically 5 to 15 mg vial in 2 to 5 mL bacteriostatic water. Compounded combinations with ipamorelin or GHRP-2 are available from US 503A pharmacies under physician oversight; the rationale is that GHRH (sermorelin) plus ghrelin-mimetic (ipamorelin) gives a stronger dual-axis pulse than either alone.
The dosing above is community practice, not a regulator-validated protocol. Trial-validated dosing for Sermorelin in humans does not exist for most use cases listed.
Risks and contraindications
Most-reported side effects: injection-site redness, occasional flushing, mild headache in the first week. Theoretical concerns common to all GH-axis stimulators: increased risk of insulin resistance with chronic use, water retention, carpal tunnel symptoms in heavy users. Endogenous-pulse stimulators are theoretically lower-risk than exogenous HGH because feedback regulation stays intact, but the long-term safety record at adult anti-aging doses is uncharacterised. Cancer history: GH stimulation can affect tumour biology, talk to an oncologist before any cycle. Contraindicated in active malignancy, severe sleep apnea, and uncontrolled diabetes.
Where this stands legally
Pediatric FDA approval withdrawn 2008 (commercial, not safety). Now sold by 503A compounding pharmacies under physician prescription. Compounding pharmacies need patient-specific clinical need to compound legally.
Not licensed by MHRA. Not commonly prescribed; some private clinics import for off-label adult use under specials regulations.
Not on EMA's approved list. Specials regulations allow named-patient use through some private clinics.
Available through some Bangkok longevity and anti-aging clinics under physician oversight. Not on Thai FDA's standard formulary; compounded or imported on patient-specific basis.
Available through some Dubai and Abu Dhabi private clinics. Compounded; patient-specific clinical justification required for MOHAP review.
TGA-permitted under specials scheme for individual patient use. Not a registered product.
Where users say they source it
Names below are sourced from community discussion. None are currently scored against the Panya 11-signal rubric. Panya does not earn commission on any of these. You can search them yourself; treat the list as a starting point for your own diligence, not an endorsement.
- Empower Pharmacy (US 503A compounding, prescription required)Pending Panya 11-signal audit
- Strive Pharmacy (US 503A compounding)Pending Panya 11-signal audit
- BDMS Wellness Clinic (Bangkok, physician-supervised)Pending Panya 11-signal audit
- Pure Rawz (research-grade subcutaneous)Pending Panya 11-signal audit
Full vendor scorecards for Sermorelin land in a follow-up sprint after lawyer review and payment processor selection. We will not route users to any vendor that scores below 70 on the rubric.
Papers worth reading directly
- Walker — Long-term effects of sermorelin acetate on growth in children. J Pediatr Endocrinol Metab, 2006 →
- Khorram et al. — Effects of GHRH(1-29) on body composition in older adults. J Clin Endocrinol Metab, 1997 →
- Ishida et al. — Growth hormone secretagogues: history, mechanisms, current uses. Endocrine, 2020 →
Panya blog posts
The credentialed clinicians have covered GLP-1 drugs for years. Here is what they actually say, not the clickbait version.
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
Adjacent reading
Track Sermorelin in your peptide journal.
Panya users log their full stack at panya.health/journey. Public-by-default with per-entry privacy controls. Vote-validated by the community.